171 related articles for article (PubMed ID: 37729613)
1. COVID-19 in patients with classic and variant hairy cell leukemia.
Kreitman RJ; Yu T; James L; Feurtado J; Eager H; Ortiz OS; Gould M; Mauter J; Zhou H; Burbelo PD; Cohen JI; Wang HW; Yuan CM; Arons E
Blood Adv; 2023 Dec; 7(23):7161-7168. PubMed ID: 37729613
[TBL] [Abstract][Full Text] [Related]
2. Long-term durable remission by cladribine followed by rituximab in patients with hairy cell leukaemia: update of a phase II trial.
Chihara D; Kantarjian H; O'Brien S; Jorgensen J; Pierce S; Faderl S; Ferrajoli A; Poku R; Jain P; Thompson P; Brandt M; Luthra R; Burger J; Keating M; Ravandi F
Br J Haematol; 2016 Sep; 174(5):760-6. PubMed ID: 27301277
[TBL] [Abstract][Full Text] [Related]
3. VH4-34+ hairy cell leukemia, a new variant with poor prognosis despite standard therapy.
Arons E; Suntum T; Stetler-Stevenson M; Kreitman RJ
Blood; 2009 Nov; 114(21):4687-95. PubMed ID: 19745070
[TBL] [Abstract][Full Text] [Related]
4. Molecular variant of hairy cell leukemia with poor prognosis.
Arons E; Kreitman RJ
Leuk Lymphoma; 2011 Jun; 52 Suppl 2(Suppl 2):99-102. PubMed ID: 21599610
[TBL] [Abstract][Full Text] [Related]
5. Phase 2 study of cladribine followed by rituximab in patients with hairy cell leukemia.
Ravandi F; O'Brien S; Jorgensen J; Pierce S; Faderl S; Ferrajoli A; Koller C; Challagundla P; York S; Brandt M; Luthra R; Burger J; Thomas D; Keating M; Kantarjian H
Blood; 2011 Oct; 118(14):3818-23. PubMed ID: 21821712
[TBL] [Abstract][Full Text] [Related]
6. Update on the biology and treatment options for hairy cell leukemia.
Jain P; Pemmaraju N; Ravandi F
Curr Treat Options Oncol; 2014 Jun; 15(2):187-209. PubMed ID: 24652320
[TBL] [Abstract][Full Text] [Related]
7. No Loose Ends: A Review of the Pharmacotherapy of Hairy Cell and Hairy Cell Leukemia Variant.
King AC; Kabel CC; Pappacena JJ; Stump SE; Daley RJ
Ann Pharmacother; 2019 Sep; 53(9):922-932. PubMed ID: 30841702
[No Abstract] [Full Text] [Related]
8. Cladribine with immediate rituximab for the treatment of patients with variant hairy cell leukemia.
Kreitman RJ; Wilson W; Calvo KR; Arons E; Roth L; Sapolsky J; Zhou H; Raffeld M; Stetler-Stevenson M
Clin Cancer Res; 2013 Dec; 19(24):6873-81. PubMed ID: 24277451
[TBL] [Abstract][Full Text] [Related]
9. Differential Expression of CD43, CD81, and CD200 in Classic Versus Variant Hairy Cell Leukemia.
Salem DA; Scott D; McCoy CS; Liewehr DJ; Venzon DJ; Arons E; Kreitman RJ; Stetler-Stevenson M; Yuan CM
Cytometry B Clin Cytom; 2019 Jul; 96(4):275-282. PubMed ID: 31077558
[TBL] [Abstract][Full Text] [Related]
10. Rituximab in the treatment of the variant of hairy cell leukaemia: a case report.
Hadzi-Pecova L; Stojanovik A; Petrusevska G; Panovska I
Prilozi; 2008 Dec; 29(2):355-60. PubMed ID: 19259059
[TBL] [Abstract][Full Text] [Related]
11. Refractory and relapsed hairy-cell leukemia (HCL): casting light on promising experimental drugs in clinical trials.
Robak T; Robak P
Expert Opin Investig Drugs; 2023 Apr; 32(4):311-324. PubMed ID: 36931901
[TBL] [Abstract][Full Text] [Related]
12. 2-chlorodeoxyadenosine (cladribine) in the treatment of hairy cell leukemia and hairy cell leukemia variant: 7-year experience in Poland.
Robak T; Błasińska-Morawiec M; Błoński J; Hellmann A; Hałaburda K; Konopka L; Kotlarek-Haus S; Potoczek S; Hansz J; Dmoszyńska A; Urasiński I; Zdziarska B; Dwilewicz-Trojaczek J; Hołowiecki J; Skotnicki AB
Eur J Haematol; 1999 Jan; 62(1):49-56. PubMed ID: 9918312
[TBL] [Abstract][Full Text] [Related]
13. Long term follow-up of a phase II study of cladribine with concurrent rituximab with hairy cell leukemia variant.
Chihara D; Arons E; Stetler-Stevenson M; Yuan C; Wang HW; Zhou H; Raffeld M; Xi L; Steinberg SM; Feurtado J; James-Echenique L; Tai CH; Patel KP; Braylan RC; Calvo KR; Maric I; Dulau-Florea A; Kreitman RJ
Blood Adv; 2021 Dec; 5(23):4807-4816. PubMed ID: 34607348
[TBL] [Abstract][Full Text] [Related]
14. Long-term follow-up of patients with hairy cell leukemia in the south of Iran.
Dehghani M; Kashkooe A; Namdari N; Majidi R; Karimi M; Haghighat S; Rezvani A; Safari N
Expert Rev Hematol; 2023 Apr; 16(4):289-295. PubMed ID: 36709461
[TBL] [Abstract][Full Text] [Related]
15. Expression of the muscle-associated gene MYF6 in hairy cell leukemia.
Arons E; Zhou H; Sokolsky M; Gorelik D; Potocka K; Davies S; Fykes E; Still K; Edelman DC; Wang Y; Meltzer PS; Raffeld M; Wiestner A; Xi L; Wang HW; Stetler-Stevenson M; Yuan C; Kreitman RJ
PLoS One; 2020; 15(2):e0227586. PubMed ID: 32040482
[TBL] [Abstract][Full Text] [Related]
16. Randomized Phase II Study of First-Line Cladribine With Concurrent or Delayed Rituximab in Patients With Hairy Cell Leukemia.
Chihara D; Arons E; Stetler-Stevenson M; Yuan CM; Wang HW; Zhou H; Raffeld M; Xi L; Steinberg SM; Feurtado J; James L; Wilson W; Braylan RC; Calvo KR; Maric I; Dulau-Florea A; Kreitman RJ
J Clin Oncol; 2020 May; 38(14):1527-1538. PubMed ID: 32109194
[TBL] [Abstract][Full Text] [Related]
17. Treatment of hairy cell leukemia-variant with cladribine.
Tetreault SA; Robbins BA; Saven A
Leuk Lymphoma; 1999 Oct; 35(3-4):347-54. PubMed ID: 10706459
[TBL] [Abstract][Full Text] [Related]
18. Treatment Outcomes Of Patients With Hairy Cell Leukaemia; A 16-Year Experience At A Tertiary Care Center In Pakistan.
Yousaf M; Khan MA; Iftikhar R; Chaudary QU; Shahbaz N; Ahmad U; Javed H
J Ayub Med Coll Abbottabad; 2022; 34(4):797-801. PubMed ID: 36566402
[TBL] [Abstract][Full Text] [Related]
19. A Case of Hairy Cell Leukemia Variant: Literature Analysis With Focus on Unmet Needs.
Kumar Upadhyay A; Kumar M; Prasad A; Shekhar S; Singh R
Cureus; 2023 Oct; 15(10):e47085. PubMed ID: 38022018
[TBL] [Abstract][Full Text] [Related]
20. Cladribine in hairy cell leukemia.
Belani R; Saven A
Hematol Oncol Clin North Am; 2006 Oct; 20(5):1109-23. PubMed ID: 16990111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
